The U.S. Food and Drug Administration is under growing calls to formally recognize a shortage of estrogen patches, a widely used treatment for menopausal symptoms and other hormonal conditions. Advocacy groups and healthcare providers have highlighted persistent supply disruptions, raising concerns about patient access to critical therapies. Regulatory action could prompt manufacturers to prioritize production and help stabilize markets amid rising demand. The issue underscores broader challenges in maintaining steady access to essential medications during periods of heightened need.
FDA facing mounting pressure to declare an estrogen patch shortage CBS News
